Wall Street Analysts Predict a 92.19% Upside in Relmada Therapeutics (RLMD): Here's What You Should Know

Shares of Relmada Therapeutics, Inc. (RLMD) have gained 46.4% over the past four weeks to close the last trading session at $6.66, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $12.8 indicates a potential upside of 92.2%.The average comprises five short-term price targets ranging from a low of $9.00 to a high of $19.00, with a standard deviation of $3.96. While the lowest esti ...